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Abstract
Objectives: For many research cohorts, it is not practical to provide a “gold-stan-
dard” mental health diagnosis. It is therefore important for mental health research
that potential alternative measures for ascertaining mental disorder status are
understood.
Methods: Data from UK Biobank in those participants who had completed the online
Mental Health Questionnaire (n = 157,363) were used to compare the classification
of mental disorder by four methods: symptom-based outcome (self-complete based
on diagnostic interviews), self-reported diagnosis, hospital data linkage, and self-
report medication.
Results: Participants self-reporting any psychiatric diagnosis had elevated risk of any
symptom-based outcome. Cohen's κ between self-reported diagnosis and symptom-
based outcome was 0.46 for depression, 0.28 for bipolar affective disorder, and 0.24
for anxiety. There were small numbers of participants uniquely identified by hospital
data linkage and medication.
Conclusion: Our results confirm that ascertainment of mental disorder diagnosis in
large cohorts such as UK Biobank is complex. There may not be one method of classi-
fication that is right for all circumstances, but an informed and transparent use of
outcome measure(s) to suit each research question will maximise the potential of UK
Biobank and other resources for mental health research.
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1 | INTRODUCTION
Mental health is a major, and growing, contributor to disability world-
wide (Whiteford, Ferrari, Degenhardt, Feigin, & Vos, 2015), prompting
the need to take advantage of all available resources in order to
progress the understanding of mental disorders and the interplay
between mental and physical health (Prince et al., 2007). To this end,
it is necessary to describe mental disorders and related traits in large-
scale epidemiological studies. The use of self-report diagnosis, admin-
istrative data, and online surveys are potential sources of data on
mental disorders that may be of use in this context, and so it is impor-
tant to understand the advantages and limitations of these measures.
1.1 | Considerations regarding indicators of mental
health
Mental disorder diagnosis is a complex specialist task, requiring
elucidation of symptoms, time course, and context (Casey & Kelly,
2007). It has not yet been possible to categorise mental disorders
using pathology or aetiology, so, in order that there can be a common
language, they have been systematised into syndromes based on signs
and symptoms (Clark, Cuthbert, Lewis-Fernández, Narrow, & Reed,
2017). However, it is not clear to what extent these syndromes reflect
true disease entities, leaving difficulties at the boundaries both from
normal variation and between different disorders (Kendell &
Jablensky, 2003). Mental health research traditionally relies on lengthy
structured or semistructured interviews to provide a “gold standard”
highly reproducible syndromic diagnosis (Haro et al., 2006; Rucker
et al., 2011), but these are costly to administer, placing a limit on
sample sizes.
Common sources of mental disorder status in studies with large
sample sizes are symptom scales or checklists, self-reported clinical
diagnoses and medication, and registries. Self-report can be captured
in a traditional interview, or using novel forms, such as online ques-
tionnaires, which vastly decrease costs of acquiring information
(Andersson, Ritterband, & Carlbring, 2008). Registry data no longer
come only from databases set up specifically for research but can be
derived from administrative data. Data linkage to these sources offers
benefits of a wider range of reports without the direct costs of
acquiring data but raises problems of interpreting and validating those
reports (Stewart & Davis, 2016).
Clinician diagnoses derived from self-reported or data linkage
should reflect the outcome of a nuanced clinical assessment, but those
people who have received a diagnosis are those who have accessed
services, whereas a large proportion of people with a mental disorder
are never formally identified as such (Goldberg & Huxley, 1980). Pas-
sage into health care will depend upon the type and severity of illness
and patient factors; receiving a diagnosis and treatment depends addi-
tionally on clinician and service factors. Such factors are vulnerable to
age and cohort effects. For example, antidepressant treatment for
those in whom the survey found symptoms of a common mental dis-
order in the previous year was almost three times more likely in 2009
(15.9%) than it had been in 1993 (5.7%; Spiers et al., 2016).
A retrospective enquiry adds recall bias for both symptoms and
diagnoses. One study estimated that ability to recall a period of sad-
ness likely to represent depression fell from 90% if it occurred in the
last year to 41% if it occurred 10 years ago (Patten et al., 2012). This
problem is not confined to mental health, because self-report of
clinician diagnosis of physical disorders including heart failure and pre-
vious cancer can be unreliable, leading mostly to underascertainment
(Nord, Mykletun, & Fosså, 2003; Okura, Urban, Mahoney, Jacobsen, &
Rodeheffer, 2004). It may be that mental disorders are also under-
reported due to perceived stigma of the disorder (Nevin, 2009;
Simon & VonKorff, 1995).
1.2 | Comparison of approaches in one resource
UK Biobank (UKB) is a research cohort for which over 503,328 people
aged 49–60 enrolled in 2007–2010. This involved questionnaires, bio-
samples, and consent for linkage of routinely collected health care
data and to take part in further waves of data collection (Sudlow
et al., 2015).
The Mental Health Outcome Consortium was formed to develop
mental health phenotyping in UKB. Mental disorder in this context
might be both an outcome and a risk factor for other health out-
comes. The consortium has focussed on two aspects: validating
administrative secondary care diagnostic codes (Davis, Coleman,
et al., 2018; Davis, Sudlow, & Hotopf, 2016) and designing an online
Mental Health Questionnaire (MHQ) to identify symptom-based out-
comes (Davis, Bashford, et al., 2018). Some of the outcomes in the
MHQ are based on diagnostic interviews and are analogous to men-
tal disorder diagnoses (e.g., depression and generalised anxiety disor-
der). Others assess other aspects of mental health such as psychotic
experiences (PEs) and self-harm. Results of the UKB MHQ are avail-
able for 157,366 participants, representing 31% of the original UKB
sample (Davis, Coleman, et al., 2018).
UKB now provides multiple indicators that could be used as a
means to identify mental disorders, none of which represents a “gold-
standard” diagnosis against which the others can be validated. This
could lead to confusion and dilemmas as to which measure to use
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for research. Although there have been studies that compare individ-
ual measures against a conventional gold standard, there are few
resources that help guide the choice of imperfect measures in large
studies such as UKB. The aim of this study is to compare four
indicators of mental health and disorder in UKB for multiple outcomes,
in order to guide future research in UKB and the design of similar
studies.
2 | METHODS
UKB is a major open science resource (Sudlow et al., 2015). Extensive
data are already available on the 503,328 volunteers in UKB (UK Bio-
bank, 2018), who responded to invitations sent by mail to people aged
40–69 who lived near to 22 assessment centres in England, Scotland,
and Wales. The composition has been documented, and it has been
noted that the volunteers are not representative of the population as
a whole (Davis, Coleman, et al., 2018; Fry et al., 2017), in particularly
under-representing people with lower socio-economic status, people
with chronic illness, and smokers. This means that the data cannot be
used to estimate population prevalence.
The methods used to develop and implement the online MHQ,
participation, and features of nonparticipants are described in Davis,
Coleman, et al. (2018). All UKB participants with a valid email address
were sent a link in 2016–2017 (n = 339,092), and 46% of those invited
submitted valid responses. People who responded had an average age
of 65 years, and 57% were female. The questionnaire is still open on
the website for participants to complete. We report findings based on
the dataset released in August 2017 (n = 157,363; 31% cohort).
The four main methods of classifying these participants' mental
health are symptom-based outcomes, self-report of diagnosis, hospital
data linkage, and self-report of medication. Brief explanations are
provided below, with the full wording, criteria, cut-offs, and code lists
available in Appendices S1–S4. Table 1 shows examples of each
method for four outcome groups that will be examined in Section 3.
Some of these groups will have more closely aligned concepts that
will allow comparison across methods, others will not. For example,
PEs are not a true “symptom,” and most people who have these
experiences do not have a psychotic disorder. Therefore, self-report
diagnosis and hospital data linkage of psychotic disorder should be
viewed as complementary concepts to PE, whereas the depression
TABLE 1 Summary of definitions for four measures (columns) that may be used to identify mental health outcomes for four example
outcome groups (rows)
Mental health
outcome
Symptom-based outcome
(see also Appendix S2) Self-report diagnosis
Hospital data linkage
1997–2015 (see also
Appendix S3)
Self-report medication
2007–2010 (see also
Appendix S4)
Depression
outcomes
Positive for major depressive
disorder ever in MHQ
(CIDI-SF lifetime).
Prevalence 24%
Endorsed clinician diagnosis
of “depression” in MHQ.
Prevalence 21%
Diagnosis of ICD-10
depressive disorder
(F32–33) on inpatient
record.
Prevalence 2%
Reported use of an
antidepressant (prevalence
5%), antipsychotic
(prevalence 0.3%), or
lithium (prevalence 0.1%)
at baseline.
Anxiety outcomes Positive for generalised
anxiety disorder ever in
MHQ (CIDI-SF lifetime).
Prevalence 7%
Endorsed clinician diagnosis
of “anxiety, nerves or
generalised anxiety
disorder” in MHQ.
Prevalence 14%
Diagnosis of ICD-10
neurotic disorders (F4×)
on inpatient record.
Prevalence 1%
Reported use of an
antidepressant at baseline.
Prevalence 5%
Bipolar affective
disorder (BPAD)
outcomes
Positive for wider bipolar
criteria ever in MHQ
(reflecting DSM-IV
hypomania/mania criteria).
Prevalence 2%
Endorsed clinician diagnosis
of “mania, hypomania,
bipolar or
manic-depression” in
MHQ.
Prevalence 1%
Diagnosis of ICD-10 mania
or BPAD (F30–31) on
inpatient record.
Prevalence 0.2%
Reported use of lithium
(prevalence 0.1%) or an
antipsychotic (prevalence
0.3%) at baseline.
Psychotic
experience (PE)
outcomes
Endorsed one or more of
four PEs ever (adapted
CIDI PE lifetime).a
Prevalence 5%
Endorsed clinician diagnosis
of “schizophrenia” or
“other psychotic illness” in
MHQ.
Prevalence 1%
Diagnosis of ICD-10
schizophrenia spectrum
(F2×) or affective
psychosis (F30.2, F31.2,
F31.5, F32.3, and F33.3)
on inpatient record.
Prevalence 0.1%
Reported use of
antipsychotic at baseline.
Prevalence 0.3%
Note. Prevalence refers to criteria positive in this sample of 157,363 UK Biobank volunteers who completed the MHQ.
Abbreviations: CIDI-SF, Composite International Diagnostic Interview Short Form; ICD-10, International Classification of Diseases 10th Revision; MHQ, Mental
Health Questionnaire.
aPEs are not true “symptoms” but outcome that can be related to psychotic disorder.
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outcome group are more akin to different methods of ascertaining the
same concept.
2.1 | Symptom-based outcomes
Lifetime depression, anxiety, bipolar affective disorder (BPAD), and
PEs make up the lifetime “symptom-based outcomes.” Lifetime
measures were felt to be important to generate controls (“never had”)
for genetic studies. Depression was assessed using the major depres-
sive disorder section of the Composite International Diagnostic
Interview Short Form (CIDI-SF), and anxiety was assessed using the
generalised anxiety disorder section of the CIDI-SF, modified to pro-
vide lifetime history (Kessler, Andrews, Mroczek, Ustun, & Wittchen,
1998; Levinson et al., 2017). They were chosen on the basis of the
ability to map on to DSM criteria, validity demonstrated by Levinson
et al., and to maximise compatibility with studies internationally that
were looking at the genetics of depression and anxiety. The CIDI-SF
uses DSM-IV criteria but is also likely to represent a DSM-5 diagnosis
as these criteria are largely unchanged (American Psychiatric Associa-
tion, 2013). Further questions assessed probable lifetime history of
DSM-defined hypomania/mania; criteria met for at least 1 week were
used as the symptom-based outcome for the BPAD outcome in this
study. Lifetime PEs, not in themselves a disorder, were assessed using
adapted questions from the CIDI (McGrath et al., 2015).
2.2 | Self-report of diagnosis
Participants were asked about clinician diagnoses of any medical
condition at the baseline UKB interview and were specifically asked
about mental disorders in the MHQ. We only use the prompted
recall from the MHQ for this analysis. The questionnaire asked
participants: “Have you been diagnosed with one or more of the
following mental health problems by a professional, even if you don't
have it currently?” Choices included “depression,” “anxiety, nerves or
generalised anxiety disorder,” “mania, hypomania, bipolar or manic-
depression,” “schizophrenia,” and “other psychotic illness.”
2.3 | Hospital data linkage
UKB (UK Biobank, 2014) has obtained structured diagnostic informa-
tion from hospital admissions data to form a virtual hospital registry,
combining Hospital Episode Statistics (HES), Scottish Morbidity
Record (SMR 1a and 1b), and Patient Episode Database for Wales
(PEDW) into a single dataset. Dates and completeness of coverage
vary: PEDW dates back to 1999, HES to 1997, and SMR to 1981.
HES and PEDW have mental health admissions in the same set as
general hospital admissions, but Scotland do not. At the time of
extraction, the Scottish mental health admissions (SMR-04) were not
available in UKB. Therefore, participants registered for the UKB in the
two Scottish centres were excluded from the comparisons that
involve hospital data linkage, leaving 146,813 participants in England
and Wales. HES and PEDW use World Health Organization (WHO;
1992) International Classification of Diseases 10th Revision to
categorise diagnosis. Cases were defined as having ever received an
International Classification of Diseases 10th Revision diagnosis code
relating to depression, anxiety, BPAD, or psychosis (see Table 1 or
Appendix S3) in main or any secondary diagnoses. Psychosis codes
included depression and BPAD where psychotic symptoms were
specified.
2.4 | Self-report of medication
At baseline (2007–2010), 6 to 10 years before completion of the
MHQ, UKB participants were asked whether they were taking any
regular medication, and a nurse interviewer took the names of
medication taken. A pre-existing code list of antidepressants, antipsy-
chotics, and lithium preparations was used to extract these data (see
Appendix S4).
2.5 | Data and analysis
The study used the UKB data release application number 16577
(application by G. B.), including valid MHQ data to June 2017 and
hospital admission data 1997–2015, extracted and analysed using R
version 3.4.3 (R Core Team, 2017) and code written by J. C. and K. D.
(Davis, Coleman, et al., 2018). Full data are available from UKB
(http://www.ukbiobank.ac.uk/register-apply/).
Confidence intervals are given at 95%, using Wilson's method for
proportions. Cohen's κ was calculated as a measure of agreement
between different methods of ascertainment for the same or equiva-
lent outcomes.
2.6 | Ethical approval
UKB has ethical approval from the North West—Haydock Research
Ethics Committee (11/NW/0382) with MHQ approved as an
amendment.
3 | RESULTS
3.1 | Self-reported diagnosis
Table 2 is a cross-tabulation of overlap between (a) self-reported
lifetime diagnosis and (b) symptom-based outcomes. Percentages
refer to the proportion of those with a self-reported diagnosis (row)
who met criteria for the specified symptom-based outcomes (column).
Of those that reported any mental disorder, 60% also met criteria for
any symptom-based outcome, whereas only 15% of those who
reported no mental disorder met any criteria. The self-report status
(any vs. none) agreed with the symptom-based status in 78%, with a κ
of 0.46. Nearly 90% of people reporting BPAD or psychotic disorder
met criteria for one or more symptom-based outcome. Regardless
which disorder was self-reported, lifetime depression was the most
likely symptom-based outcome.
Depression, anxiety, and BPAD self-reported diagnoses and
symptom-based outcomes are compared in Table 3. Depression
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outcomes had a κ of 0.46, anxiety outcomes have a κ of 0.28, and
BPAD outcomes have a κ of 0.24.
3.2 | Hospital data linkage
Table 4 shows the partial overlap between the symptom-based out-
comes, self-reported diagnosis, and hospital data linkage. The combi-
nation of three sources identified depression in 48,794 participants,
but the hospital data linkage only identified 3,034 (6%) of these, most
of whom (1,937) were also identified by both of the other two
methods. Hospital data linkage identified 5% of anxiety cases and 9%
of BPAD cases identified by any means. Of those with hospital data-
linkage diagnosis of psychotic illness (213), the symptom-based out-
come of PE was present in 67% (143).
3.3 | Self-reported medication
The snapshot view of selected self-report medication use provided at
the baseline assessment is shown in Tables . Antidepressants were
being taken by 8,616 (5.9%) participants, whereas antipsychotics and
lithium were prescribed to less than 500 people each. Eighty-three
per cent of all people taking antidepressants were identified as hav-
ing a lifetime history of depression through one of the three
methods. Only half of the participants taking antipsychotics reported
PEs or had a diagnosis of psychosis (229/470, 49%), although a fur-
ther 35% (163/470) had an indicator of affective disorder. Lithium
was almost confined to those identified as having an affective
disorder—79% BPAD, 20% depression without evidence of BPAD.
3.4 | Combinations
Table 4 shows the results of combining symptom-based outcomes,
self-reported diagnosis, and hospital data linkage in an additive
TABLE 2 Symptom-based outcomes (SBOs, columns) and self-reported diagnoses (SRs, rows)
[BLANK]
Overall
SBO
No. of SBO \ SR (SBO|SR %)
n
Prev. in
sample
(%) Depression Anxiety
Wide
bipolar
definition PEa Any SBO No SBO
Overall n 157,363 NA 37,434 11,111 2,396 7,803 44,598 112,765
Prev. in
sample (%)
NA NA 24 7 2 5 28 72
SR Depression 33,424 21 20,714 (62%) 7,173 (21%) 1,314 (4%) 3,239 (10%) 22,651 (68%) 10,773 (32%)
Anxiety 22,036 14 11,632 (53%) 5,711 (26%) 813 (4%) 2,051 (9%) 13,365 (61%) 8,670 (39%)
BPAD 837 1 599 (72%) 248 (30%) 391 (47%) 358 (43%) 737 (88%) 100 (12%)
Psychosis 723 1 491 (68%) 247 (34%) 187 (26%) 458 (63%) 635 (88%) 88 (12%)
Panic disorder 8,704 6 4,555 (52%) 2,424 (28%) 399 (5%) 1,024 (12%) 5,273 (61%) 3,431 (39%)
Eating disorder 1,851 1 1,048 (57%) 495 (27%) 101 (5%) 279 (15%) 1,201 (65%) 650 (35%)
Personality
disorder
385 <1 270 (70%) 171 (44%) 63 (16%) 141 (37%) 324 (84%) 61 (16%)
Any self-report 48,230 31 25,495 (53%) 9,081 (19%) 1,721 (4%) 4,255 (9%) 28,739 (60%) 19,491 (40%)
No self-report 109,133 69 11,938 (11%) 2,030 (2%) 675 (1%) 3,548 (3%) 15,859 (15%) 93,274 (85%)
Note. Numbers define participants with both stated symptom-based outcome and self-report (SBO \ SR), and % is the proportion of participants with
given self-report also having given symptom-based outcome (SBO|SR). For definitions of symptom-based-outcomes, please see Appendix S2.
Abbreviations: BPAD, bipolar affective disorder; NA, not applicable; PE, psychotic experience.
aPEs are not true “symptoms” but outcome that can be related to psychotic disorder.
TABLE 3 The overlap of self-report (A) and symptom-based outcome (B) for selected diagnoses, showing the intersection (A \ B), proportion
overlap (B|A and A|B), and agreement (κ)
Mental
Health
Outcome
No. of
self-report
(A)
No. of
symptom-based
outcome (B)
No. of self-report and
symptom-based outcome
(A \ B)
% Symptom-based outcome
given self-report (B| A)
% Self-report given
symptom-based outcome
(A| B) κ
Depression 33,424 37,434 20,714 62 55 0.46
Anxiety 22,036 11,111 5,711 26 51 0.28
BPAD 837 2,396 391 47 16 0.24
Abbreviation: BPAD, bipolar affective disorder.
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manner for depression, anxiety, and BPAD. In all disorders,
symptom-based outcomes, self-report, and hospital data linkage
each contribute unique cases—but in different proportions for each
disorder.
Combinations of outcomes for the common mental disorders of
depression and anxiety are further explored in Table S1 and
accompanying text. The symptom-based outcomes were positive for
depression or anxiety in 37,629 participants. Self-reported or data-
linkage diagnosis of depression or anxiety or self-reported antidepres-
sant medication is positive in 47,321 participants, including 25,920
(55%) who were positive and 21,401 (45%) who were negative on life-
time symptom-based outcomes.
4 | DISCUSSION
In this study, we have compared methods of ascertainment for mental
health outcomes in UKB from the position that none is equivalent to
the outcome of a gold-standard psychiatric interview. This situation is
common in large nonspecialist research resources, and there is a need
for resources to help with decision making when researchers are
faced with a choice of imperfect measures.
We found that the magnitude of the overlap between the mea-
sures differed depending on the disorders. Depression outcomes were
the most prevalent and had the most overlap between self-report and
symptom-based outcomes (κ = 0.46). The proportion of participants
with symptom-based outcome who self-reported a diagnosis was
55%, similar to the 61% of people of a similar age in a German study
who were positive for lifetime depression on the Structured Clinical
Interview for the DSM Axis-I (SCID-I) who self-reported a diagnosis
(Stuart et al., 2014).
A self-reported diagnosis of “anxiety, nerves or generalised anxi-
ety disorder” had less overlap with the corresponding symptom-based
outcome (κ = 0.28), a symptom-based outcome for depression (53%)
being more likely than anxiety (26%). Combining depression and
generalised anxiety may be an acceptable strategy in population stud-
ies, where the concepts are largely overlapping (Gask, Klinkman,
Fortes, & Dowrick, 2008), and in our data, this led to an improvement
in agreement between self-report and symptom-based outcomes over
anxiety, but not depression (κ = 0.46).
The conventional models of BPAD, with dramatic and disabling
symptoms, would predict a high proportion to have been formally
identified, but our symptom-based outcome of BPAD was deliberately
fairly wide to facilitate research into the wider spectrum of BPAD
(Phillips & Kupfer, 2013) and would include many people who would
meet the DSM criteria for BPAD type II as well as BPAD type
I. People with BPAD type II will be less likely to be formally diagnosed
or require inpatient treatment and hence will be less commonly identi-
fied by a hospital data linkage. Of those with BPAD symptom-based
outcome, 16% self-reported clinician diagnosis and 9% had data-
linkage diagnosis. Self-report diagnosis is somewhat higher in this
study than in a similar Finnish population study (Perälä et al., 2007)
where only 6% of those positive for the CIDI-BPAD outcome self-T
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reported a diagnosis. This may be evidence of a cohort effect of
different diagnostic behaviour or patient awareness between coun-
tries or over time.
PE and psychotic disorder are not equivalent, but complementary
categories. We found that PE was almost 10 times more common
than psychotic disorder reported by the participant and/or hospital
data linkage (prevalence of PE 4.7% vs. psychotic disorder diagnosis
0.5%). The Finnish study (Perälä et al., 2007) found the rates of PE
and psychosis diagnosis to be 3.0% and 3.3%, respectively. The lower
prevalence of PE may be partly due to the mode of administration
being interview, as PEs are more likely to be endorsed in self-
completed measures (Linscott & Van Os, 2013). The higher levels of
diagnosis of a psychosis diagnosis may be partly because the registry
used in the Finnish study goes back further in time but may also be
related to participation bias. The Finnish study was a modest size
study aiming at representativeness, with a participation rate of 93% of
TABLE 5B Self-report of any antipsychotic for participants with PEs or psychotic disorder, BPAD, and depression outcomes
Outcome PEa BPAD Depression Nil
Symptom-based outcome 203/7,390 (2.7%) 103/2,247 (4.6%) 300/35,140 (0.9%)
Self-report 163/684 (23.8%) 135/783 (17.2%) 277/31,381 (0.9%)
Hospital data linkage 84/213 (39.4%) 68/245 (27.8%) 105/2,858 (3.7%)
Self-report antipsychotic
given above criteria
229/7,686 (3.1%) 161/2,709 (5.9%) Excluding PE
42/1,890 (2.2%)
354/47,278 (0.7%) Excluding PE
and BPAD 121/41,359 (0.3%)
78/95,879 (0.1%)
Any criteria given
self-report antipsychotic
229/470 (48.7%) Excluding PE
42/470 (8.9%)
Excluding PE and BPAD
121/470 (25.7%)
78/470 (16.6%)
Note. SeeTable 1 and Appendices S1–S4 for definitions. Self-reported psychotropic use at baseline against psychiatric indication by three criteria:
symptom-based outcome, self-report diagnosis, and hospital data linkage. % = proportion of cases screening positive for each criteria who reported
medication use, except bottom row. Bottom row shows proportion of all participants reporting medication use who screened positive for each disorder.
Abbreviations: BPAD, bipolar affective disorder; PE, psychotic experience.
aPEs are not true “symptoms” but outcome that can be related to psychotic disorder. Self-report and hospital data linkage, in contrast, represent psychotic
disorders.
TABLE 5C Self-report of lithium prescription for participants with BPAD and depression outcomes
Outcome BPAD Depression Nil
Symptom-based outcome 73/2,247 (3.2%) 127/35,140 (0.4%) NA
Self-report 119/783 (15.2%) 111/31,381 (0.4%) NA
Hospital data linkage 67/245 (27.3%) 50/2,858 (1.7%) NA
Self-report lithium given above criteria 131/2,709 (4.8%) 146/47,278 (0.3%) Excluding BPAD 34/45,195 (0.1%) 1/98,909 (0.0%)
Any criteria given self-report lithium 131/166 (78.9%) Excluding BPAD 34/166 (20.5%) 1/166 (0.6%)
Note. SeeTable 1 and Appendices S1–S4 for definitions. Self-reported psychotropic use at baseline against psychiatric indication by three criteria:
symptom-based outcome, self-report diagnosis, and hospital data linkage. % = proportion of cases screening positive for each criteria who reported
medication use, except bottom row. Bottom row shows proportion of all participants reporting medication use who screened positive for each disorder.
Abbreviations: BPAD, bipolar affective disorder; NA, not applicable.
TABLE 5A Self-report of any antidepressant for participants with depression and anxiety outcomes
Outcome Depression Anxiety Nil
Symptom-based outcome 5,352/35,140 (15.2%) 2,355/10,415 (22.6%)
Self-report diagnosis 6,378/31,381 (20.3%) 4,427/26,124 (16.9%)
Hospital data linkage 1,492/2,858 (52.2%) 533/1,770 (30.1%)
Self-report antidepressant given above criteria 7,137/47,278 (15.1%) 5,123/31,071 (16.5%) 923/88,706 (1.0%)
Excluding depression
556/10,829 (5.1%)
Any criteria given self-report antidepressant 7,137/8,616 (82.8%) Excluding depression
556/8616 (6.5%)
923/8616 (10.7%)
Note. SeeTable 1 and Appendices S1–S4 for definitions. Self-reported psychotropic use at baseline against psychiatric indication by three criteria:
symptom-based outcome, self-report diagnosis, and hospital data linkage. % = proportion of cases screening positive for each criteria who reported
medication use, except bottom row. Bottom row shows proportion of all participants reporting medication use who screened positive for each disorder.
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those selected, whereas UKB followed a different model, requesting
volunteers from the community (Davis, Coleman, et al., 2018; Fry
et al., 2017): People with an enduring psychotic disorder may have
been less willing and/or able to volunteer.
Of the three self-reported medication classes investigated, antide-
pressants were the most commonly reported. Even so, antidepressant
prescription could only identify 15–17% of people with those
symptom-based outcomes of depression and anxiety. This is inevita-
ble given the snapshot nature of the ascertainment of medication, the
“treatment gap” (Kohn, Saxena, Levav, & Saraceno, 2004), and appro-
priate management of lifetime mental disorder without medication.
Surprisingly, only 49% of those taking antipsychotics were positive on
a measure of PE or psychosis, 35% had an affective disorder, and 13%
neither. This fits with literature on the extended and off-label pre-
scribing of antipsychotics (Carton et al., 2015; Pringsheim, Gardner, &
Patten, 2015).
4.1 | Method of ascertainment
Symptom-based outcomes do not require participants to have
accessed care to detect a disorder, making them potentially the most
sensitive out of the measures we compared, although the retrospec-
tive nature is likely to reduce sensitivity for distant episodes. By ana-
lysing participant responses to particular questions, it may also be
possible to also look at subtypes or specific phenotypes or manipulate
thresholds. Symptoms were collected using CIDI-SF modules. The
CIDI was created for the WHO programme and supported by them,
although the short form is not currently supported by the WHO. Such
measures are popular in surveys (McDowell, 2006; van Ballegooijen,
Riper, Cuijpers, van Oppen, & Smit, 2016), although they can be over-
inclusive as they lack the ability to rule out other causes of the same
symptoms (e.g., thyroid disturbance mimicking anxiety). Alternatives
to the CIDI-SF may have different, possibly better, performance—but
this has not been tested.
Administration of self-report diagnostic scales online is now an
established practice (Andersson et al., 2008; Nguyen, Klein, Meyer,
Austin, & Abbott, 2015), but there are generally less validation data
available for measures administered electronically or via the Inter-
net (Buchanan, 2003; van Ballegooijen et al., 2016). The perfor-
mance of the CIDI-SF depression module that was administered
in the online MHQ has however been positively validated in at
least two independent studies (Carlbring et al., 2002; Levinson
et al., 2017).
Self-reported clinician diagnosis is an easily obtainable measure,
which allowed the MHQ to ask about a wide range of outcomes. As
predicted, the diagnosis prevalence was lower than the symptom-
based outcome prevalence in the MHQ in most categories. The
exception was generalised anxiety—which may be related to the
wording of the question regarding anxiety diagnosis being vague.
The presence of self-reported diagnosis was associated with a
greater risk of all symptom-based outcomes, not just for equivalent
outcomes, which reflects the co-morbidities between disorders
often unrecognised (Oiesvold et al., 2013; Whiteford et al., 2015).
Another sources of self-reported diagnosis in UKB are those reported
during the baseline assessment. On that occasion, participants were
not prompted to recall specific diagnoses and had to disclose them
face to face. The prevalence of self-reported mental prevalence was
lower on that occasion, with depression reported by only 6.5%, as
opposed to 21% at the MHQ. This is likely to do with the prompted
recall but may also be due to stigma during a face-to-face interview
and new diagnoses since baseline.
The hospital data linkage provided by UKB leverages national sta-
tistics to identify outcomes that are commonly documented in hospi-
tal admissions. The nature and patient pathway of mental disorders
mean only the most severe cases are likely to be the cause of an
admission (Goldberg & Huxley, 1980). Moreover, these episodes may
have happened many decades ago, before 1997 when the data for
England start. Most mentions of mental disorder will therefore be sec-
ondary diagnoses in participants admitted to hospital with other prob-
lems, which have not been specifically validated (Davis, Coleman,
et al., 2018). In this study, the low numbers identified in hospital data
linkage, with high levels of lifetime symptom-based outcomes in those
individuals, suggest a specific but insensitive measure. Registries
based on data linkage to outpatient attendance or primary care
consultations may give a more sensitive measure, although it is likely
to be more complex to define cases given the myriad of coding types
in these records (John et al., 2016; Spiranovic, Matthews, Scanlan, &
Kirkby, 2016).
The use of self-reported medication data is potentially problem-
atic. Bias in recall of medication is very common, perhaps more so in
psychotropics (Gnjidic, Du, Pearson, Hilmer, & Banks, 2017). Objective
ascertainment of prescribed medication is likely to be provided in the
future by linkage to primary care data, and in some studies, pharmacy
claims data have been successfully used to supplement self-reported
medication (Drieling et al., 2016; Gnjidic et al., 2017). However, there
will remain the likelihood that medication will have poor sensitivity
for case finding in mental health, as psychotropics will never be
prescribed to all of those with a lifetime history, and poor specific-
ity as they are prescribed for many things outside of mental health.
In the case of using medication in the UKB to supplement MHQ
findings, there is the added problem of the snapshot of medication
taken being ascertained around 7 years prior to the MHQ adminis-
tration and therefore being unable to reflect new-onset disorders
and prescriptions.
Algorithmic approaches can be taken that exploit the strengths of
each measure to produce a compound measure. Algorithms will
include combining cases from two or more outcome types as done for
this genomic study of depression in UKB using baseline self-report
and hospital diagnosis (Howard et al., 2018). Items can also be
grouped into new criteria as was done to define mood disorders at
baseline (Smith et al., 2013). Another approach, previously suggested
in the case–control definitions defined by the UKB mental health out-
comes group, uses symptom-based outcomes for cases but excludes
from controls those who self-reported diagnosis or had data-linkage
diagnosis or suggestive medication. Taking the BPAD row from
Table 4 as a simplified example: 2,247 people were positive for the
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symptom-based outcome, and 155,119 were negative; out of those
who did not meet criteria, 177 had a hospital diagnosis of BPAD,
326 more reported a diagnosis of BPAD, and 35 more reported taking
lithium (Table 5c)—all of these are suggestive of BPAD. To minimise
false positives and false negatives in the BPAD item, these 538 sug-
gestive participants can be excluded from cases and controls, leaving
2,247 cases and 154,581 controls. Further algorithms incorporating
hospital and primary care data for severe mental illness and common
mental disorder in the full cohort are due to be published by UKB in
2019–2020—as has already been done for stroke and myocardial
infarction.
4.2 | Does it matter?
We have shown that different methods of ascertainment of mental
disorder can result in different groups of participants being identified
as cases. This poor agreement between methods of ascertainment
could be problematic for research consistency and reproducibility.
However, there is evidence that even with poor agreement at the
level of disorder diagnosis, there can be similarity at the biological
level. For example, a twin study (Torvik et al., 2018) reported that
cases derived from interview diagnoses had limited overlap with those
selected by data linkage (primary and secondary)—for depression,
36% interview positive were also on primary care registry, whereas
48% of those in registry were interview positive, with less overlap for
anxiety (21%/46%) and alcohol use disorder (3%/33%). Despite this,
the genetic features identified in the interview and registry groups
were highly correlated within each diagnosis, approaching unity for
depression and anxiety disorders. It remains to be seen whether the
same will be true for the different cohorts selected in UKB—certainly
focussing exclusively on very highly selected outcomes such as hospi-
tal data-linkage means including biases to do with health service
utilisation that may not relate to underlying mental health need
(Roberts et al., 2018).
Genome-wide association studies (GWASs) often pool cases and
controls from different cohorts. Studies that define DSM disorders
using clinical interview, self-report diagnosis, symptom-based out-
comes, or combinations thereof might be combined in order to
achieve the necessary size of the sample. The results will then depend
heavily on whether the biology converges on a single disorder or con-
verges on the different definitions (Vrieze, Iacono, & McGue, 2012). A
massed GWAS of depression (Wray et al., 2018) included cases that
were defined at interview (PGC29, GenScot), treatment registers
(iPSYCHE, GERA), self-report diagnosis (23andMe), and a combination
(DeCODE, UKB [prior to MHQ results]) showed strong genetic
correlation between the studies. The combined GWAS also showed
enrichment of the targets of antidepressant treatment. These results
suggest that weakening the phenotype can reveal interesting and
relevant biology.
On some occasions, we have found that different measures have
indicated different disorders for the same individuals, which could
lead to confusion in research concentrated on a narrowly defined
diagnosis. However, this reflects established findings of a high degree
of co-morbidity and cross-over in mental disorders (Davis, Bashford,
et al., 2018; First, 2005; Gask et al., 2008), probably due to shared
aetiology and pathology (Cross-Disorder Group of the Psychiatric
Genomics Consortium, 2013; Elliott, Romer, Knodt, & Hariri, 2018)
that is poorly translated into categorical diagnostic classifications.
Other models for understanding mental disorder have been
suggested, and some of these ideas could be translated to measures
for research in large cohorts (Carcone & Ruocco, 2017; Clark et al.,
2017; Vrieze et al., 2012), but diagnostic categories continue to be
utilised widely.
4.3 | Implications
For users of UKB, the symptom-based outcomes defined in the MHQ
offer advantages: They will select a large proportion of the partici-
pants with a likely disorder; many have been validated externally; and
there is scope to customise, such as for different thresholds. How-
ever, self-report, hospital data linkage, and medication may also be
able to identify unique cases and may have high predictive validity. In
some scenarios, it would seem sensible to add cases together.
Another approach is to use the symptom-based outcome to define
the cases and define the controls to exclude positives on the other
measures. For some questions, the sample and measures in the MHQ
may be too limiting, and unprompted baseline self-report sup-
plemented by hospital data linkage will have to be used (Howard
et al., 2018), which are highly selected, until primary care data and
algorithms are released. Co-morbidity between mental disorders is
high, and interpretation of this may need consideration. Given the
high degree of flexibility that UKB affords, researchers should con-
sider the breadth and granularity of the mental health diagnosis
needed alongside the consideration of the variables used to define
them, so that the most appropriate combination of measure and out-
come can be chosen to best address the research question.
Other studies could learn from the experience in UKB in three
main ways. First, under-recognition, fluctuating course, and self-
management of most mental disorder means questions about lifetime
symptoms are needed to identify those who have never had a disor-
der. Second, co-morbidity between the mental disorders is high, and
this needs to be acknowledged in the design and interpretation of
MHQs. Third, registries, data linkage, and measures of treatment will
underestimate numbers of cases of mental disorder but do provide
further information.
4.4 | Strengths and weaknesses
UKB aims to produce and adjudicate outcomes in a clear, expert-
led manner. The Mental Health Outcomes Consortium has worked
with UKB to implement the MHQ, and the present analysis was
planned to clarify the different mental health definitions now pre-
sent in UKB.
The MHQ had a very good response rate compared with previous
UKB online questionnaires, and it gives an unparalleled sample size
for a mental health survey. However, like much observational
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research, it is subject to participation bias in its volunteers (Davis, Col-
eman, et al., 2018; Fry et al., 2017). Given that participation in
research can be patterned by mental health (Atherton, Fuller, Shep-
herd, Strachan, & Power, 2008; Knudsen, Hotopf, Skogen, verland, &
Mykletun, 2010), it may be that people with severe symptoms of
mental disorder were less likely to volunteer or complete the MHQ,
as might be suggested by the small number of people with a hospital
data-linkage diagnosis of a psychotic disorder, which may limit
generalisability of our findings to other settings.
The measures in the MHQ were felt to be the most suitable for
defining lifetime mental disorders within the constraints of a short
survey and maintaining compatibility with existing genetic studies.
The online CIDI-SF has been validated, but only for depression in the
lifetime version. The questions used to assess for symptoms of
mania/hypomania have not been externally validated. For both instru-
ments, it is likely that the lifetime version is affected by recall bias.
Further, the UKB data linkage and medication aspects are currently
limited. Hospital admission data will capture few with mental
disorders, so we will welcome the forthcoming linkages to primary
care data. Medication was self-reported and on a single occasion that
was 7 to 10 years prior to the symptom-based outcome: Again, it may
be better after linkage to primary care data.
5 | CONCLUSIONS
Large cohort studies provide great potential for interesting discovery,
but using these datasets involves confronting problems with defini-
tions of disorders, data quality, and incomplete coverage. Mental
health research is further hampered the challenge that many mental
disorders are under-recognised and under-represented in health care
data. UKB is a rich observational resource due to its size, extensive
baseline measures, and linkages to national administrative records.
The utility of UKB for mental health research has been improved by
the UKB MHQ. We have shown that, in general, the number of cases
identified by lifetime symptom-based diagnosis exceeds those identi-
fied with self-report diagnosis, hospital data linkage, and psychotropic
medication, with an overlap between measures that differs between
the disorders under study. The advantage of symptom-based lifetime
classification of mental disorder is sensitivity across the severity spec-
trum, and many of the symptom-based outcomes have been validated
against psychiatric interview elsewhere. However, other mental health
ascertainment methods could complement symptom-based outcome
measures in research. UKB and other open science projects lend
themselves to innovative, well-described, and reported approaches
that can be scrutinised by the community. The ideas and results of this
exploratory analysis highlight the strengths and limitations of both the
indicators in large cohort studies, and the mental disorder diagnosis
itself, which we hope will assist those planning to address the impor-
tant questions in mental health and wider research.
ACKNOWLEDGEMENTS
This work was supported by the NIHR Biomedical Research Centre at
South London and Maudsley and King's College London. The views
expressed are those of the author(s) and not necessarily those of the
NHS, the National Institute of Health Research, the Department of
Health, or UK Biobank. High performance computing facilities were
funded with capital equipment grants from the Guy's and St Thomas's
Charity (TR130505) and Maudsley Charity (980).
FUNDING INFORMATION
M. A. and A. M. are supported by a Wellcome Trust Strategic Award
(Reference 104036/Z/14/Z). A. M. is supported by an MRC Grant
(Reference MC_PC_17209) and The Sackler Trust. B. C. is funded by
the Scottish Executive Chief Scientist Office (DTF/14/03) and by The
Dr Mortimer and Theresa Sackler Foundation. W. L. is supported by
the National Institute for Health Research (NIHR) Collaboration for
Leadership in Applied Health Research and Care South West
Peninsula.
DECLARATION OF INTEREST STATEMENT
We have read and understood the author guidelines of ethical con-
duct and wish to declare the following: B. C. reports grants from the
Scottish Executive Chief Scientist Office during the conduct of the
study. M. H. reports grants for IMI RADAR-CNS and personal fees as
an expert witness outside the submitted work. G. B. reports grants
from National Institute for Health Research during the conduct of the
study and support from Illumina Ltd. and the European Commission
outside the submitted work.
ORCID
Katrina A.S. Davis https://orcid.org/0000-0001-5945-4646
Breda Cullen https://orcid.org/0000-0002-7259-9505
Anamaria Brailean https://orcid.org/0000-0002-6334-7349
Jonathan R.I. Coleman https://orcid.org/0000-0002-6759-0944
Matthew Hotopf https://orcid.org/0000-0002-3980-4466
REFERENCES
American Psychiatric Association (2013). Highlights of changes from
DSM-IV-TR to DSM-5. In APA (Ed.), Diagnostic and statistical manual
of mental disorders (fifth ed.). Arlington, VA: American Psychiatric Asso-
ciation Publishing. https://dsm.psychiatryonline.org/doi/full/10.1176/
appi.books.9780890425596.changes
Andersson, G., Ritterband, L. M., & Carlbring, P. (2008). Primer for the
assessment, diagnosis and delivery of Internet interventions for
(mainly) panic disorder. Lessons learned from our research groups.
Clinical Psychologist, 12(1), 1–8. https://doi.org/10.1080/
13284200802069027
Atherton, K., Fuller, E., Shepherd, P., Strachan, D. P., & Power, C. (2008).
Loss and representativeness in a biomedical survey at age 45 years:
10 of 12 DAVIS ET AL.
1958 British birth cohort. Journal of Epidemiology and Community
Health, 62(3), 216–223. https://doi.org/10.1136/jech.2006.058966
Buchanan, T. (2003). Internet-based questionnaire assessment: Appropri-
ate use in clinical contexts. Cognitive Behaviour Therapy, 32(3),
100–109. https://doi.org/10.1080/16506070310000957
Carcone, D., & Ruocco, A. C. (2017). Six years of research on the National
Institute of Mental Health's research domain criteria (RDoC) initiative:
A systematic review. Frontiers in Cellular Neuroscience, 11, 46.
Carlbring, P., Forslin, P., Ljungstrand, P., Willebrand, M., Strandlund, C.,
Ekselius, L., & Andersson, G. (2002). Is the Internet-administered CIDI-
SF equivalent to a clinician-administered SCID interview? Cognitive
Behaviour Therapy, 31(4), 183–189. https://doi.org/10.1080/
165060702321138573
Carton, L., Cottencin, O., Lapeyre-Mestre, M., Geoffroy, P., Favre, J.,
Simon, N., … Rolland, B. (2015). Off-label prescribing of
antipsychotics in adults, children and elderly individuals: A
systematic review of recent prescription trends. Current Pharmaceuti-
cal Design, 21(23), 3280–3297. https://doi.org/10.2174/
1381612821666150619092903
Casey, P., & Kelly, B. (2007). Classification of psychiatric disorders. In
F. J. Fish, P. Casey, & B. Kelly (Eds.), Fish's clinical psychopathology:
Signs and symptoms in psychiatry (pp. 1–13). London: RCPsych
Publications.
Clark, L. A., Cuthbert, B., Lewis-Fernández, R., Narrow, W. E., &
Reed, G. M. (2017). Three approaches to understanding and
classifying mental disorder: ICD-11, DSM-5, and the National Institute
of Mental Health's Research Domain Criteria (RDoC). Psychological Sci-
ence in the Public Interest, 18(2), 72–145. https://doi.org/10.1177/
1529100617727266
Cross-Disorder Group of the Psychiatric Genomics Consortium (2013).
Identification of risk loci with shared effects on five major psychiatric
disorders: A genome-wide analysis. The Lancet, 381(9875),
1371–1379.
Davis, K. A. S., Bashford, O., Jewell, A., Shetty, H., Stewart, R. J.,
Sudlow, C. L. M., & Hotopf, M. (2018). Using data linkage to electronic
patient records to assess the validity of selected mental health diagno-
ses in English Hospital Episode Statistics (HES). PLoS ONE, 13,
e0195002. https://doi.org/10.1371/journal.pone.0195002
Davis, K. A. S., Coleman, J., Adams, M., Allen, N., Breen, G., Cullen, B., …
Hotopf, M. (2018). Mental health in UK Biobank—Development,
implementation and results from an online questionnaire completed
by 157,366 participants. BJPsych Open, 4, 83–90. https://doi.org/10.
1192/bjo.2018.12
Davis, K. A. S., Sudlow, C. L., & Hotopf, M. (2016). Can mental health diag-
noses in administrative data be used for research? A systematic review
of the accuracy of routinely collected diagnoses. BMC Psychiatry,
16(1), 263. https://doi.org/10.1186/s12888-016-0963-x
Drieling, R. L., LaCroix, A. Z., Beresford, S. A., Boudreau, D. M.,
Kooperberg, C., & Heckbert, S. R. (2016). Validity of self-reported
medication use compared with pharmacy records in a cohort of
older women: Findings from the women's health initiative. American
Journal of Epidemiology, 184(3), 233–238. https://doi.org/10.1093/
aje/kwv446
Elliott, M. L., Romer, A., Knodt, A. R., & Hariri, A. R. (2018). A connectome-
wide functional signature of transdiagnostic risk for mental illness. Bio-
logical Psychiatry, 84, 452–459. https://doi.org/10.1016/j.biopsych.
2018.03.012
First, M. B. (2005). Mutually exclusive versus co-occurring diagnostic cate-
gories: The challenge of diagnostic comorbidity. Psychopathology,
38(4), 206–210. https://doi.org/10.1159/000086093
Fry, A., Littlejohns, T. J., Sudlow, C., Doherty, N., Adamska, L., Sprosen, T.,
… Allen, N. E. (2017). Comparison of sociodemographic and health-
related characteristics of UK Biobank participants with the general
population. American Journal of Epidemiology, 186, 1026–1034.
https://doi.org/10.1093/aje/kwx246
Gask, L., Klinkman, M., Fortes, S., & Dowrick, C. (2008). Capturing com-
plexity: The case for a new classification system for mental disorders
in primary care. European Psychiatry, 23(7), 469–476. https://doi.org/
10.1016/j.eurpsy.2008.06.006
Gnjidic, D., Du, W., Pearson, S. A., Hilmer, S. N., & Banks, E. (2017). Ascer-
tainment of self-reported prescription medication use compared with
pharmaceutical claims data. Public Health Res Pract, 27(4). https://doi.
org/10.17061/phrp27341702
Goldberg, D. P., & Huxley, P. (1980). Mental illness in the community: The
pathway to psychiatric care. London: Tavistock Publications Limited
(Republished by Routledge 2011).
Haro, J. M., Arbabzadeh-Bouchez, S., Brugha, T. S., de Girolamo, G.,
Guyer, M. E., Jin, R., … Kessler, R. C. (2006). Concordance of the Com-
posite International Diagnostic Interview Version 3.0 (CIDI 3.0) with
standardized clinical assessments in the WHO World Mental Health
surveys. International Journal of Methods in Psychiatric Research, 15(4),
167–180. https://doi.org/10.1002/mpr.196
Howard, D. M., Adams, M. J., Shirali, M., Clarke, T.-K., Marioni, R. E.,
Davies, G., … McIntosh, A. M. (2018). Genome-wide association study
of depression phenotypes in UK Biobank identifies variants in excit-
atory synaptic pathways. Nature Communications, 9(1), 1470. https://
doi.org/10.1038/s41467-018-03819-3
John, A., McGregor, J., Fone, D., Dunstan, F., Cornish, R., Lyons, R. A., &
Lloyd, K. R. (2016). Case-finding for common mental disorders of anxi-
ety and depression in primary care: An external validation of routinely
collected data. BMC Medical Informatics and Decision Making, 16(1), 35.
https://doi.org/10.1186/s12911-016-0274-7
Kendell, R., & Jablensky, A. (2003). Distinguishing between the validity and
utility of psychiatric diagnoses. American Journal of Psychiatry, 160(1),
4–12. https://doi.org/10.1176/appi.ajp.160.1.4
Kessler, R. C., Andrews, G., Mroczek, D., Ustun, B., & Wittchen, H. U.
(1998). The World Health Organization composite international diag-
nostic interview short-form (CIDI-SF). International Journal of Methods
in Psychiatric Research, 7(4), 171–185. https://doi.org/10.1002/
mpr.47
Knudsen, A. K., Hotopf, M., Skogen, J. C., verland, S., & Mykletun, A.
(2010). The health status of nonparticipants in a population-based
health study: The Hordaland Health Study. American Journal of Epide-
miology, 172(11), 1306–1314. https://doi.org/10.1093/aje/kwq257
Kohn, R., Saxena, S., Levav, I., & Saraceno, B. (2004). The treatment gap in
mental health care. Bulletin of the World Health Organization, 82(11),
858–866.
Levinson, D., Potash, J., Mostafavi, S., Battle, A., Zhu, X., & Weissman, M.
(2017). Brief assessment of major depression for genetic studies: Vali-
dation of CIDI-SF screening with SCID interviews. European
Neuropsychopharmacology, 27, S448. https://doi.org/10.1016/j.
euroneuro.2016.09.514
Linscott, R., & Van Os, J. (2013). An updated and conservative systematic
review and meta-analysis of epidemiological evidence on psychotic
experiences in children and adults: On the pathway from proneness
to persistence to dimensional expression across mental disorders.
Psychological Medicine, 43(6), 1133–1149. https://doi.org/10.1017/
S0033291712001626
McDowell, I. (2006). Anxiety & depression. In Measuring health: A guide to
rating scales and questionnaires (pp. 273–393). New York: Oxford Uni-
versity Press.
McGrath, J. J., Saha, S., Al-Hamzawi, A., Alonso, J., Bromet, E. J.,
Bruffaerts, R., … Fayyad, J. (2015). Psychotic experiences in the gen-
eral population: A cross-national analysis based on 31 261 respon-
dents from 18 countries. JAMA Psychiatry, 72(7), 697–705. https://
doi.org/10.1001/jamapsychiatry.2015.0575
Nevin, R. L. (2009). Low validity of self-report in identifying recent mental
health diagnosis among US service members completing Pre-
Deployment Health Assessment (PreDHA) and deployed to
DAVIS ET AL. 11 of 12
Afghanistan, 2007: A retrospective cohort study. BMC Public Health,
9(1), 376. https://doi.org/10.1186/1471-2458-9-376
Nguyen, D. P., Klein, B., Meyer, D., Austin, D. W., & Abbott, J.-A. M.
(2015). The diagnostic validity and reliability of an internet-based
clinical assessment program for mental disorders. Journal of Medical
Internet Research, 17(9), e218–e218. https://doi.org/10.2196/jmir.
4195
Nord, C., Mykletun, A., & Fosså, S. D. (2003). Cancer patients' awareness
about their diagnosis: A population-based study. Journal of Public
Health, 25(4), 313–317. https://doi.org/10.1093/pubmed/fdg076
Oiesvold, T., Nivison, M., Hansen, V., Skre, I., Ostensen, L., & Sorgaard, K.
(2013). Diagnosing comorbidity in psychiatric hospital: Challenging the
validity of administrative registers. BMC Psychiatry, 13(1), 13. https://
doi.org/10.1186/1471-244X-13-13
Okura, Y., Urban, L. H., Mahoney, D. W., Jacobsen, S. J., &
Rodeheffer, R. J. (2004). Agreement between self-report question-
naires and medical record data was substantial for diabetes, hyperten-
sion, myocardial infarction and stroke but not for heart failure. Journal
of Clinical Epidemiology, 57(10), 1096–1103. https://doi.org/10.1016/
j.jclinepi.2004.04.005
Patten, S. B., Williams, J. V. A., Lavorato, D. H., Bulloch, A. G. M.,
D'Arcy, C., & Streiner, D. L. (2012). Recall of recent and more remote
depressive episodes in a prospective cohort study. Social Psychiatry
and Psychiatric Epidemiology, 47(5), 691–696. https://doi.org/10.
1007/s00127-011-0385-5
Perälä, J., Suvisaari, J., Saarni, S. I., Kuoppasalmi, K., Isometsä, E.,
Pirkola, S., … Lönnqvist, J. (2007). Lifetime prevalence of psychotic and
bipolar I disorders in a general population. Archives of General Psychia-
try, 64(1), 19–28. https://doi.org/10.1001/archpsyc.64.1.19
Phillips, M. L., & Kupfer, D. J. (2013). Bipolar disorder diagnosis: Challenges
and future directions. The Lancet, 381(9878), 1663–1671. https://doi.
org/10.1016/S0140-6736(13)60989-7
Prince, M., Patel, V., Saxena, S., Maj, M., Maselko, J., Phillips, M. R., &
Rahman, A. (2007). No health without mental health. Lancet, 370(9590),
859–877. https://doi.org/10.1016/S0140-6736(07)61238-0
Pringsheim, T., Gardner, D., & Patten, S. B. (2015). Adjunctive treatment
with quetiapine for major depressive disorder: Are the benefits of
treatment worth the risks? BMJ [British Medical Journal], 350. https://
doi.org/10.1136/bmj.h569
R CoreTeam (2017). R: A language and environment for statistical computing
(Version 3.4.3). Vienna, Austria: R Foundation for Statistical Comput-
ing. https://www.R-project.org/:
Roberts, T., Miguel Esponda, G., Krupchanka, D., Shidhaye, R., Patel, V., &
Rathod, S. (2018). Factors associated with health service utilisation for
common mental disorders: A systematic review. BMC Psychiatry, 18(1),
262. https://doi.org/10.1186/s12888-018-1837-1
Rucker, J., Newman, S., Gray, J., Gunasinghe, C., Broadbent, M., Brittain, P.,
… McGuffin, P. (2011). OPCRIT+: An electronic system for psychiatric
diagnosis and data collection in clinical and research settings. The Brit-
ish Journal of Psychiatry, 199(2), 151–155. https://doi.org/10.1192/
bjp.bp.110.082925
Simon, G. E., & VonKorff, M. (1995). Recall of psychiatric history in cross-
sectional surveys: Implications for epidemiologic research.
Epidemiologic Reviews, 17(1), 221–227. https://doi.org/10.1093/
oxfordjournals.epirev.a036180
Smith, D. J., Nicholl, B. I., Cullen, B., Martin, D., Ul-Haq, Z., Evans, J., …
Pell, J. P. (2013). Prevalence and characteristics of probable major
depression and bipolar disorder within UK biobank: Cross-sectional
study of 172,751 participants. PLoS ONE, 8(11), e75362. https://doi.
org/10.1371/journal.pone.0075362
Spiers, N., Qassem, T., Bebbington, P., McManus, S., King, M., Jenkins, R.,
… Brugha, T. S. (2016). Prevalence and treatment of common mental
disorders in the English national population, 1993–2007. The British
Journal of Psychiatry, 209(2), 150–156. https://doi.org/10.1192/bjp.
bp.115.174979
Spiranovic, C., Matthews, A., Scanlan, J., & Kirkby, K. C. (2016). Increasing
knowledge of mental illness through secondary research of electronic
health records: Opportunities and challenges. Advances in Mental
Health, 14(1), 14–25. https://doi.org/10.1080/18387357.2015.
1063635
Stewart, R., & Davis, K. A. S. (2016). ‘Big data’ in mental health research:
Current status and emerging possibilities. Social Psychiatry and Psychi-
atric Epidemiology, 51(8), 1055–1072. https://doi.org/10.1007/
s00127-016-1266-8
Stuart, A. L., Pasco, J. A., Jacka, F. N., Brennan, S. L., Berk, M., &
Williams, L. J. (2014). Comparison of self-report and structured clinical
interview in the identification of depression. Comprehensive Psychiatry,
55(4), 866–869. https://doi.org/10.1016/j.comppsych.2013.12.019
Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., …
Collins, R. (2015). UK Biobank: An open access resource for identifying
the causes of a wide range of complex diseases of middle and old age.
PLoS Medicine, 12(3), e1001779. https://doi.org/10.1371/journal.
pmed.1001779
Torvik, F. A., Ystrom, E., Gustavson, K., Rosenström, T. H., Bramness, J. G.,
Gillespie, N., … Reichborn-Kjennerud, T. (2018). Diagnostic and genetic
overlap of three common mental disorders in structured interviews
and health registries. Acta Psychiatrica Scandinavica, 137(1), 54–64.
https://doi.org/10.1111/acps.12829
UK Biobank. (2014). Mapping inpatient hospital data across England, Scot-
land and Wales. Retrieved from http://biobank.ctsu.ox.ac.uk/crystal/
docs/inpatient_mapping.pdf (accessed 04 April 2019)
UK Biobank. (2018). UK Biobank Data Showcase. Retrieved from http://
biobank.ctsu.ox.ac.uk/crystal/ (accessed 04 April 2019)
van Ballegooijen, W., Riper, H., Cuijpers, P., van Oppen, P., & Smit, J. H.
(2016). Validation of online psychometric instruments for common
mental health disorders: A systematic review. BMC Psychiatry, 16(1),
45. https://doi.org/10.1186/s12888-016-0735-7
Vrieze, S. I., Iacono, W. G., & McGue, M. (2012). Confluence of genes,
environment, development, and behavior in a post Genome-Wide
Association Study world. Development and Psychopathology, 24(4),
1195–1214. https://doi.org/10.1017/s0954579412000648
Whiteford, H. A., Ferrari, A. J., Degenhardt, L., Feigin, V., & Vos, T. (2015).
The global burden of mental, neurological and substance use disorders:
An analysis from the Global Burden of Disease Study 2010. PLoS ONE,
10(2). https://doi.org/10.1371/journal.pone.0116820
World Health Organization. (1992). The ICD-10 classification of mental and
behavioural disorders: Clinical descriptions and diagnostic guidelines.
http://www.who.int/classifications/icd/icdonlineversions/en/
(accessed 04 April 2019)
Wray, N. R., Ripke, S., Mattheisen, M., Trzaskowski, M., Byrne, E. M.,
Abdellaoui, A., … The Major Depressive Disorder Working Group of
the Psychiatric Genomics Consortium (2018). Genome-wide associa-
tion analyses identify 44 risk variants and refine the genetic architec-
ture of major depression. Nature Genetics, 50(5), 668–681. https://doi.
org/10.1038/s41588-018-0090-3
SUPPORTING INFORMATION
Additional supporting information may be found online in the
Supporting Information section at the end of this article.
How to cite this article: Davis KAS, Cullen B, Adams M, et al.
Indicators of mental disorders in UK Biobank—A comparison
of approaches. Int J Methods Psychiatr Res. 2019;e1796.
https://doi.org/10.1002/mpr.1796
12 of 12 DAVIS ET AL.
